Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Christopher M Haqq"'
Autor:
Thomas Williams, Martin Steinbuck, Peter DeMuth, Xavier Cabana-Puig, Erica Palmer, Mimi M Jung, Jeff Zhang, Christopher M Haqq
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fff8e02658ab4c698c0cb776574c337e
Autor:
Christopher M Haqq, James R Perry, Lochana M Seenappa, Haley VanWyk, Amy M Tavares, Esther Welkowsky, Peter C DeMuth, Lisa K McNeil
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/1c71d7ed4fa54b02b40337420eac3bf9
Autor:
Mark Jesus M Magbanua, Ritu Roy, Eduardo V Sosa, Vivian Weinberg, Scott Federman, Michael D Mattie, Millie Hughes-Fulford, Jeff Simko, Katsuto Shinohara, Christopher M Haqq, Peter R Carroll, June M Chan
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24004 (2011)
Studies suggest that micronutrients may modify the risk or delay progression of prostate cancer; however, the molecular mechanisms involved are poorly understood. We examined the effects of lycopene and fish oil on prostate gene expression in a doubl
Externí odkaz:
https://doaj.org/article/ec6dade537a44548b820e607a36c0505
Autor:
Lochana M. Seenappa, Aniela Jakubowski, Martin P. Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane Fontenot, Francois Villinger, Lisa K. McNeil, Peter C. DeMuth
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-16 (2022)
Abstract Despite the success of currently authorized vaccines for the reduction of severe COVID-19 disease risk, rapidly emerging viral variants continue to drive pandemic waves of infection, resulting in numerous global public health challenges. Pro
Externí odkaz:
https://doaj.org/article/0e0c165500e944c68281b4df4a9887a4
Autor:
David M. Hyman, Christopher M. Haqq, Willis H. Navarro, Drew W. Rasco, Joyce F. Liu, Karen A. Cadoo, Vicky Makker, Nicholas A. Cangemi, Jessica J. Tao
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6b016706b2cbd200409c2cca3ee589
https://doi.org/10.1158/1078-0432.22471076
https://doi.org/10.1158/1078-0432.22471076
Autor:
David M. Hyman, Christopher M. Haqq, Willis H. Navarro, Drew W. Rasco, Joyce F. Liu, Karen A. Cadoo, Vicky Makker, Nicholas A. Cangemi, Jessica J. Tao
Development of diffuse telangiectasias (highlighted by blue arrows) occurred on the upper chest, back, and face in a patient with ovarian granulosa cell tumor treated at the 0.75 mg/kg Q2W dose of STM 434.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35ce66c798dff05e7ee1a7a121762df0
https://doi.org/10.1158/1078-0432.22471079.v1
https://doi.org/10.1158/1078-0432.22471079.v1
Autor:
David M. Hyman, Christopher M. Haqq, Willis H. Navarro, Drew W. Rasco, Joyce F. Liu, Karen A. Cadoo, Vicky Makker, Nicholas A. Cangemi, Jessica J. Tao
Purpose:STM 434 is a soluble receptor ligand trap targeting activin A, a protein in the TGFβ family that plays important roles in growth, differentiation, and cancer cachexia. This study evaluated the safety, antitumor activity, and metabolic effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d0c219c5c6e710835150abcc51ec4d
https://doi.org/10.1158/1078-0432.c.6527765
https://doi.org/10.1158/1078-0432.c.6527765
Autor:
David M. Hyman, Christopher M. Haqq, Willis H. Navarro, Drew W. Rasco, Joyce F. Liu, Karen A. Cadoo, Vicky Makker, Nicholas A. Cangemi, Jessica J. Tao
Change and end of treatment values for albumin, hemoglobin, and absolute lymphocytes among the 32 patients are summarized below. Abbreviations: SD, stable disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222f3a5240c21531a713b6b4c6fc53ba
https://doi.org/10.1158/1078-0432.22471070.v1
https://doi.org/10.1158/1078-0432.22471070.v1
Autor:
Lochana M. Seenappa, Aniela Jakubowski, Martin P. Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane Fontenot, Francois Villinger, Lisa K. McNeil, Peter C. DeMuth
Despite the success of currently authorized vaccines for the reduction of severe COVID-19 disease risk, rapidly emerging viral variants continue to drive pandemic waves of infection, resulting in numerous global public health challenges. Progress wil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec426d3cada80ad1391f086454c34147
https://doi.org/10.1101/2022.05.19.492649
https://doi.org/10.1101/2022.05.19.492649
Autor:
Dylan J. Drakes, Abdulraouf M. Abbas, Jacqueline Shields, Martin P. Steinbuck, Aniela Jakubowski, Lochana M. Seenappa, Christopher M. Haqq, Peter C. DeMuth
While T cell receptor (TCR)-modified T cell therapies have shown promise against solid tumors, overall therapeutic benefits in clinical practice have been modest due in part to suboptimal T cell persistence and activation in vivo, alongside the possi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c75470b10dcf0ff3789539378b3fae3d
https://doi.org/10.1101/2022.05.05.490779
https://doi.org/10.1101/2022.05.05.490779